Hiroshige Yoshioka

机构：Kansai Medical University, Saitama Medical University Hospital, Dokkyo Medical University Saitama Medical Center, Social Insurance Saitama Chuo Hospital, Dokkyo Medical University, Saitama Medical University · ORCID：0000-0001-7724-0481

发表论文 359 篇 · 总被引 17444 次 · h-index 51

代表论文

• Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer (2024 · Journal of Clinical Oncology · 被引 158)
• Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 136)
• Risk Factors for Locoregional Relapse After Segmentectomy: Supplementary Analysis of the JCOG0802/WJOG4607L Trial (2024 · Journal of Thoracic Oncology · 被引 54)
• Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial (2025 · Annals of Oncology · 被引 39)
• Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non–Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834 (2025 · Journal of Clinical Oncology · 被引 33)
• A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET) (2025 · Journal of Thoracic Oncology · 被引 19)